Ketamine’s clinical journey spans more than six decades, evolving from a battlefield anesthetic to a groundbreaking therapeutic tool in mental health. Its history reflects a convergence of neurobiological discovery, clinical intuition, and unmet therapeutic needs, leading to its current role in the treatment of depression, addiction, and treatment-resistant conditions. This
Recent research suggests ayahuasca-assisted psychotherapy may support people facing acute grief. In a structured therapeutic setting, ayahuasca was associated with reduced grief severity, fewer prolonged-grief symptoms, and greater post-traumatic growth. The study compared ayahuasca-assisted therapy, psychotherapy alone, and no intervention, finding the strongest improvements when ritual, psychotherapy, and community support
Depression, anxiety and chronic stress are associated with the loss and retraction of dendritic spines, disrupting communication between key brain regions involved in emotion, memory and decision-making. This disconnection reduces cognitive flexibility and promotes rumination and rigid negative patterns. Ketamine and other psychedelics have been shown to rapidly enhance neuroplasticity
Treatment-resistant depression affects up to one third of patients with major depressive disorder and is linked to severe impairment and suicide risk. Real-world clinical data show that ketamine offers rapid antidepressant effects, with meaningful symptom reduction in nearly half of treated patients and remission in around one third. Benefits often
Grief after the death of a loved one is a universal experience, yet for some people it becomes prolonged, intense, and deeply disabling. Prolonged grief is associated with persistent yearning, emotional pain, and functional impairment, and often does not respond adequately to antidepressants or conventional psychotherapy alone. Emerging research suggests
Prolonged or complicated grief affects around 10% of bereaved people and is marked by persistent longing, intense emotional distress, and functional impairment. Current evidence shows only moderate benefits from psychotherapy and no proven efficacy of medication alone. Recent research highlights psychedelic-assisted therapies as promising alternatives. Ketamine-assisted therapy may support grief
The information on this website is intended for healthcare professionals authorized to prescribe or dispense medications who practice their profession in Spain. Therefore, specialized training is required to interpret it correctly. The mentioned product may have a different authorized data sheet in other countries. By clicking the “Accept” button, you confirm that you are a healthcare professional authorized to prescribe or dispense medications and that you wish to access the information on this website in that capacity.
